RS60430B1 - Jedinjenja 4-amino-imidazohinolina - Google Patents
Jedinjenja 4-amino-imidazohinolinaInfo
- Publication number
- RS60430B1 RS60430B1 RS20200734A RSP20200734A RS60430B1 RS 60430 B1 RS60430 B1 RS 60430B1 RS 20200734 A RS20200734 A RS 20200734A RS P20200734 A RSP20200734 A RS P20200734A RS 60430 B1 RS60430 B1 RS 60430B1
- Authority
- RS
- Serbia
- Prior art keywords
- amino
- imidazoquinoline compounds
- imidazoquinoline
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14165349 | 2014-04-22 | ||
EP15716824.6A EP3134402B1 (en) | 2014-04-22 | 2015-04-20 | 4-amino-imidazoquinoline compounds |
PCT/EP2015/058465 WO2015162075A1 (en) | 2014-04-22 | 2015-04-20 | 4-amino-imidazoquinoline compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
RS60430B1 true RS60430B1 (sr) | 2020-07-31 |
Family
ID=50489008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20200734A RS60430B1 (sr) | 2014-04-22 | 2015-04-20 | Jedinjenja 4-amino-imidazohinolina |
Country Status (22)
Country | Link |
---|---|
US (2) | US9334268B2 (sr) |
EP (1) | EP3134402B1 (sr) |
JP (1) | JP6367366B2 (sr) |
KR (1) | KR101905292B1 (sr) |
CN (1) | CN106232599B (sr) |
AR (1) | AR100137A1 (sr) |
BR (1) | BR112016017261B1 (sr) |
CA (1) | CA2938280C (sr) |
DK (1) | DK3134402T3 (sr) |
ES (1) | ES2804101T3 (sr) |
HR (1) | HRP20201043T1 (sr) |
HU (1) | HUE049656T2 (sr) |
LT (1) | LT3134402T (sr) |
MA (1) | MA39898B1 (sr) |
MX (1) | MX2016013689A (sr) |
PL (1) | PL3134402T3 (sr) |
PT (1) | PT3134402T (sr) |
RS (1) | RS60430B1 (sr) |
RU (1) | RU2698902C2 (sr) |
SI (1) | SI3134402T1 (sr) |
TW (1) | TWI607007B (sr) |
WO (1) | WO2015162075A1 (sr) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3008055A1 (en) * | 2015-12-14 | 2017-06-22 | Glaxosmithkline Biologicals S.A. | Pegylated imidazoquinolines as tlr7 and tlr8 agonists |
CN113603675A (zh) | 2015-12-17 | 2021-11-05 | 默克专利有限公司 | 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途 |
JP7022702B2 (ja) | 2016-05-23 | 2022-02-18 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 第二級アミド基を有するベンズアゼピンジカルボキサミド化合物 |
CN109153648B (zh) | 2016-05-23 | 2022-07-22 | 豪夫迈·罗氏有限公司 | 具有叔酰胺官能团的苯并氮杂卓二甲酰胺化合物 |
EP3468963B1 (en) | 2016-06-12 | 2021-10-27 | F. Hoffmann-La Roche AG | Dihydropyrimidinyl benzazepine carboxamide compounds |
CN115317603A (zh) | 2016-07-07 | 2022-11-11 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
JP7125385B2 (ja) | 2016-08-08 | 2022-08-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Tlr7/8アンタゴニストおよびそれらの使用 |
IL265921B1 (en) | 2016-10-14 | 2024-01-01 | Prec Biosciences Inc | Transgenic meganonucleases specific for recognition sequences in the hepatitis B virus genome |
AU2017366621B2 (en) | 2016-11-28 | 2021-07-29 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof |
US10757485B2 (en) * | 2017-08-25 | 2020-08-25 | Honda Motor Co., Ltd. | System and method for synchronized vehicle sensor data acquisition processing using vehicular communication |
WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
AU2018385693A1 (en) | 2017-12-15 | 2020-06-18 | Silverback Therapeutics, Inc. | Antibody construct-drug conjugate for the treatment of hepatitis |
US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
EP3728255B1 (en) | 2017-12-20 | 2022-01-26 | 3M Innovative Properties Company | Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
CN108299421B (zh) * | 2018-01-30 | 2020-09-29 | 中国医学科学院药用植物研究所 | 一种瑞喹莫德的酰化衍生物及制备方法与应用 |
EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
US11370788B2 (en) | 2018-02-28 | 2022-06-28 | 3M Innovative Properties Company | Substituted imidazo[4,5-c]quinoline compounds with an N-1 branched group |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
WO2019193543A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
CN112218864B (zh) | 2018-05-24 | 2023-09-08 | 3M创新有限公司 | N-1支链环烷基取代的咪唑并[4,5-c]喹啉化合物、组合物和方法 |
CN110526918B (zh) * | 2018-05-25 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 一种吡唑并杂芳基类衍生物的晶型及制备方法 |
KR20210013624A (ko) * | 2018-05-25 | 2021-02-04 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피라졸로헤테로아릴 유도체의 하이드로클로라이드의 결정 형태 및 제조 방법 |
CN110526917B (zh) * | 2018-05-25 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 一种吡唑并杂芳基类衍生物的可药用盐、晶型及其制备方法 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
JP2021534180A (ja) | 2018-08-16 | 2021-12-09 | イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. | 置換4−アミノ−1H−イミダゾ[4,5−c]キノリン化合物およびその製造の改良法 |
EP4306523A3 (en) * | 2018-09-07 | 2024-01-24 | Birdie Biopharmaceuticals, Inc. | Imidazoquinoline compounds and uses thereof |
AU2019337652A1 (en) * | 2018-09-12 | 2021-03-18 | Silverback Therapeutics, Inc. | Antibody conjugates of toll-like receptor agonists |
SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
KR20210141461A (ko) * | 2019-02-01 | 2021-11-23 | 캔웰 바이오테크 리미티드 | 이미다조퀴놀린 아민 유도체, 약제학적 조성물, 이의 용도 |
JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチドおよびそのプロドラッグ |
CN113543851A (zh) | 2019-03-07 | 2021-10-22 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
WO2020257407A1 (en) | 2019-06-19 | 2020-12-24 | Silverback Therapeutics, Inc. | Anti-mesothelin antibodies and immunoconjugates thereof |
CN112174903B (zh) * | 2019-07-01 | 2022-07-12 | 清华大学 | Tlr8的小分子调节剂 |
US11339159B2 (en) * | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
CN114555799A (zh) | 2019-09-30 | 2022-05-27 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
AU2020358726A1 (en) | 2019-10-01 | 2022-04-07 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
EP4051270A4 (en) * | 2019-10-29 | 2024-02-28 | Prime Reach Trading Ltd | 4-AMINO-IMODAZOCINOLINE COMPOUNDS AND USES THEREOF |
EP4069729A1 (en) | 2019-12-06 | 2022-10-12 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
EP4138909A1 (en) | 2020-04-19 | 2023-03-01 | Englmeier, Ludwig | Prophylaxis and treatment of coronavirus infection |
WO2021231941A1 (en) * | 2020-05-14 | 2021-11-18 | Merck Healthcare Kgaa | Tlr7/8 antagonists for the treatment of coronavirus infections |
EP4153590A1 (en) * | 2020-05-21 | 2023-03-29 | Ohio State Innovation Foundation | Functional lipid derivatives and uses thereof |
AU2021300362A1 (en) | 2020-07-01 | 2023-02-23 | ARS Pharmaceuticals, Inc. | Anti-ASGR1 antibody conjugates and uses thereof |
WO2022153157A1 (en) * | 2021-01-13 | 2022-07-21 | Pfizer Inc. | A crystalline form of 2-((4-amino-2-(ethoxymethyl)-6,7-dimethyl-1 h-imidazo[4,5-c]pyridin-1-yl)methyl)-2-methylpropane-1,3-diol free base |
WO2022170002A1 (en) * | 2021-02-03 | 2022-08-11 | Seagen Inc. | Immunostimulatory compounds and conjugates |
TW202304524A (zh) | 2021-04-10 | 2023-02-01 | 美商普方生物製藥美國公司 | Folr1結合劑、其結合物及使用方法 |
EP4326768A1 (en) | 2021-04-23 | 2024-02-28 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
WO2023081237A1 (en) * | 2021-11-03 | 2023-05-11 | Regents Of The University Of Minnesota | Toll-like receptor agonists and antagonists and uses thereof |
WO2024030577A1 (en) * | 2022-08-03 | 2024-02-08 | Seagen Inc. | Immunostimulatory anti-pd-l1-drug conjugates |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0872478T3 (da) | 1991-03-01 | 2003-03-31 | Minnesota Mining & Mfg | Mellemprodukter til fremstilling af 1-substituerede, 2-substituerede 1H-imidazo[4,5-c]quinolin-4-aminer |
US6451810B1 (en) * | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
DE60230340D1 (de) * | 2001-11-16 | 2009-01-22 | 3M Innovative Properties Co | N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung |
NZ545536A (en) * | 2003-09-05 | 2010-04-30 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C |
WO2005076783A2 (en) * | 2003-12-04 | 2005-08-25 | 3M Innovative Properties Company | Sulfone substituted imidazo ring ethers |
TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯 |
SI2268618T1 (sl) | 2008-03-03 | 2015-09-30 | Novartis Ag | Spojine in sestavki kot modulatorji aktivnosti TLR |
ES2545275T3 (es) | 2008-11-06 | 2015-09-09 | Ventirx Pharmaceuticals, Inc. | Métodos de síntesis de derivados de benzazepinas |
MX2011008500A (es) | 2009-02-11 | 2011-09-26 | Univ California | Moduladores del receptor tipo toll y tratamiento de enfermedades. |
ES2732999T3 (es) | 2009-08-07 | 2019-11-27 | Glaxosmithkline Biologicals Sa | Derivados de oxoadenina lipidada |
JP2013512859A (ja) | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | トール様受容体(tlr)を介して作用するイミダゾキノリン |
EP2563366A4 (en) | 2010-04-30 | 2013-11-20 | Univ California | USE OF PHOSPHOLIPID CONJUGATES FROM SYNTHETIC TLR7 AGONISTS |
CN103458902B (zh) | 2010-10-01 | 2017-11-07 | 帆德制药股份有限公司 | Tlr激动剂和联合治疗的治疗应用 |
WO2012066336A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
BR112013031039B1 (pt) | 2011-06-03 | 2020-04-28 | 3M Innovative Properties Co | compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado |
WO2012167801A1 (ru) | 2011-06-07 | 2012-12-13 | Uglovsky Sergey Evgenievich | Импульсная установка для преобразования низкопотенциальной тепловой энергии в электрическую |
WO2013033345A1 (en) | 2011-08-30 | 2013-03-07 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
WO2013067597A1 (en) * | 2011-11-09 | 2013-05-16 | Ascend Biopharmaceuticals Pty Ltd | Immunomodulatory conjugates |
WO2013166110A1 (en) | 2012-05-02 | 2013-11-07 | Yale University | Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms) |
-
2015
- 2015-04-20 AR ARP150101179A patent/AR100137A1/es active IP Right Grant
- 2015-04-20 EP EP15716824.6A patent/EP3134402B1/en active Active
- 2015-04-20 CN CN201580020712.2A patent/CN106232599B/zh active Active
- 2015-04-20 LT LTEP15716824.6T patent/LT3134402T/lt unknown
- 2015-04-20 KR KR1020167032523A patent/KR101905292B1/ko active IP Right Grant
- 2015-04-20 ES ES15716824T patent/ES2804101T3/es active Active
- 2015-04-20 JP JP2016564006A patent/JP6367366B2/ja active Active
- 2015-04-20 RU RU2016144386A patent/RU2698902C2/ru active
- 2015-04-20 BR BR112016017261-2A patent/BR112016017261B1/pt active IP Right Grant
- 2015-04-20 MX MX2016013689A patent/MX2016013689A/es unknown
- 2015-04-20 CA CA2938280A patent/CA2938280C/en active Active
- 2015-04-20 HU HUE15716824A patent/HUE049656T2/hu unknown
- 2015-04-20 PL PL15716824T patent/PL3134402T3/pl unknown
- 2015-04-20 PT PT157168246T patent/PT3134402T/pt unknown
- 2015-04-20 WO PCT/EP2015/058465 patent/WO2015162075A1/en active Application Filing
- 2015-04-20 DK DK15716824.6T patent/DK3134402T3/da active
- 2015-04-20 SI SI201531273T patent/SI3134402T1/sl unknown
- 2015-04-20 RS RS20200734A patent/RS60430B1/sr unknown
- 2015-04-20 MA MA39898A patent/MA39898B1/fr unknown
- 2015-04-21 TW TW104112767A patent/TWI607007B/zh active
- 2015-04-22 US US14/692,968 patent/US9334268B2/en active Active
-
2016
- 2016-04-07 US US15/093,481 patent/US9447097B2/en active Active
-
2020
- 2020-07-01 HR HRP20201043TT patent/HRP20201043T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PL3134402T3 (pl) | 2020-11-02 |
CA2938280C (en) | 2022-07-12 |
JP6367366B2 (ja) | 2018-08-01 |
ES2804101T3 (es) | 2021-02-03 |
AR100137A1 (es) | 2016-09-14 |
JP2017513883A (ja) | 2017-06-01 |
RU2698902C2 (ru) | 2019-09-02 |
MA39898B1 (fr) | 2020-08-31 |
RU2016144386A (ru) | 2018-05-22 |
US9447097B2 (en) | 2016-09-20 |
PT3134402T (pt) | 2020-07-02 |
BR112016017261A8 (pt) | 2020-06-16 |
MX2016013689A (es) | 2017-01-20 |
WO2015162075A1 (en) | 2015-10-29 |
US20150299194A1 (en) | 2015-10-22 |
CN106232599B (zh) | 2018-11-16 |
HUE049656T2 (hu) | 2020-10-28 |
DK3134402T3 (da) | 2020-07-20 |
US9334268B2 (en) | 2016-05-10 |
KR101905292B1 (ko) | 2018-11-21 |
TW201544505A (zh) | 2015-12-01 |
CA2938280A1 (en) | 2015-10-29 |
LT3134402T (lt) | 2020-07-10 |
HRP20201043T1 (hr) | 2020-10-16 |
RU2016144386A3 (sr) | 2018-11-27 |
BR112016017261B1 (pt) | 2022-04-19 |
SI3134402T1 (sl) | 2020-08-31 |
TWI607007B (zh) | 2017-12-01 |
US20160222010A1 (en) | 2016-08-04 |
CN106232599A (zh) | 2016-12-14 |
KR20160138317A (ko) | 2016-12-02 |
EP3134402A1 (en) | 2017-03-01 |
EP3134402B1 (en) | 2020-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181797T1 (hr) | Spojevi aminopiridiloksipirazola | |
SI3134402T1 (sl) | 4-amino-imidazokinolinske spojine | |
GB201415573D0 (en) | Compounds | |
GB201411418D0 (en) | Compounds | |
GB201410430D0 (en) | Compounds | |
GB201402431D0 (en) | Compounds | |
GB201417369D0 (en) | Compounds | |
GB201404987D0 (en) | Compounds | |
GB201416186D0 (en) | Compounds | |
GB201406591D0 (en) | Compounds | |
GB201419228D0 (en) | Compounds | |
GB201406956D0 (en) | Compounds | |
AP2017009778A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
GB201419264D0 (en) | Compounds | |
GB201412660D0 (en) | Compounds | |
GB201504956D0 (en) | Compounds | |
GB201407695D0 (en) | Compounds | |
GB201405361D0 (en) | Compounds | |
GB201707536D0 (en) | Compounds | |
GB201421711D0 (en) | Compounds | |
GB201421019D0 (en) | Compounds | |
GB201421020D0 (en) | Compounds | |
GB201420594D0 (en) | Compounds | |
GB201420593D0 (en) | Compounds | |
GB201419722D0 (en) | Compounds |